tipranavir
Trade name: aptivus
Approved
Jun 22, 2005
Tipranavir (PNU-140690, trade mark APTIVUS) is a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Tipranavir has potent in vitro activity against a variety of HIV-1 laboratory strains and clinical isolates, including those resistant to ritonavir, as well as HIV-2. The drug is launched in several countries, including the US and in the EU. APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor. — NCATS
Clinical trial activity
60 trials · 15 clinical orgs · 1 marketing orgs
Earliest trial started Jan 1, 1999 (NCT02238314)
Timeline
1990s
- Jan 1, 1999
Boehringer Ingelheim — Earliest Phase 2 Sponsor(trial)
2000s
- Jan 1, 2000
Boehringer Ingelheim — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2003
Boehringer Ingelheim — Earliest Phase 3 Sponsor(trial)
- Jun 22, 2005
Boehringer Ingelheim — Earliest FDA Approval
- Jun 22, 2005
Boehringer Ingelheim — NDA Secondary Org
- Jun 22, 2005
Boehringer Ingelheim — NDA Organization
Indications
Approved for
Mechanism of action
Q72874 inhibitor
Approval history
- approvedPriority reviewAcceleratedJun 22, 2005
Chemistry & pharmacology
SMILES
CCC[C@@]2(CCC1=CC=CC=C1)CC(O)=C([C@H](CC)C3=CC=CC(NS(=O)(=O)C4=NC=C(C=C4)C(F)(F)F)=C3)C(=O)O2- Mol. weight
- 602.664 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaTipranavir ↗
- NCATSZZT404XD09 ↗
- ChEMBLCHEMBL222559 ↗
Also known as
- 3'-((1r)-1-((6r)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide
- aptivus
- aptivus
- aptivus
- aptivus
- aptivus
- pnu 140690
- pnu 140690
- pnu-140690
- pnu-140690
- tipranavir
- tipranavir
- tipranavir
- tipranavir
- tipranavir
- tipranavir
- tipranavir
- tipranavir
- tipranavir
- tipranavir
- tipranavir
- tipranavir, (r-(r*,r*))-isomer
- tipranavir, (s-(r*,r*))-isomer
- tipranavir, (s-(r*,s*))-isomer
- tipranivir
- u-140690
- u-140690
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03631732 | Phase 3 | Aug 28, 2018 | Gilead Sciences |
| NCT01923311 | Phase 2/Phase 3 (Phase 3) | Aug 26, 2013 | Gilead Sciences |
| NCT01743521 | Phase 4 | Jan 1, 2013 | Johnson and Johnson, University of New South Wales |
| NCT00708162 | Phase 3 | Jul 1, 2008 | Gilead Sciences |
| NCT02244190 | Phase 1 | Apr 1, 2008 | Boehringer Ingelheim |
| NCT00537394 | Phase 3 | Jan 1, 2008 | AIDS Clinical Trials Group, Brown University, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Diego |
| NCT00607958 | Phase 4 | Dec 1, 2007 | Badalona Hospital Germans Trias i Pujol, Fundacio Lluita Contra la SIDA |
| NCT00530920 | Phase 2 | Oct 1, 2007 | Boehringer Ingelheim |
| NCT00517192 | Phase 3 | Sep 1, 2007 | Boehringer Ingelheim |
| NCT02251795 | Phase 1 | Aug 1, 2007 | Boehringer Ingelheim |
| NCT00447902 | Phase 3 | Mar 1, 2007 | Boehringer Ingelheim |
| NCT00440271 | Phase 3 | Feb 1, 2007 | Boehringer Ingelheim |
| NCT00344123 | Phase 1 | Feb 1, 2007 | Boehringer Ingelheim, Johns Hopkins University |
| NCT02226978 | Phase 1 | Feb 1, 2007 | Boehringer Ingelheim |
| NCT02229760 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2006 | Boehringer Ingelheim |
| NCT00486330 | N/A | May 1, 2006 | Boehringer Ingelheim, Yale University |
| NCT02226991 | Phase 1 | Apr 1, 2006 | Boehringer Ingelheim |
| NCT02227017 | Phase 1 | Feb 1, 2006 | Boehringer Ingelheim |
| NCT02259855 | Phase 1 | Jan 1, 2006 | Boehringer Ingelheim |
| NCT02243553 | Phase 1 | Jan 1, 2006 | Boehringer Ingelheim |
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 52 | 50 | 4 | 1999 |
| Gilead Sciences | For profit | 3 | 3 | 1 | 2008 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 2 | 2 | 2 | 2005 |
| Fundacio Lluita Contra la SIDA | Academic/Hospital | 2 | 0 | 2 | 2005 |
| University of New South Wales | Academic/Hospital | 2 | 2 | 1 | 2003 |
| AIDS Clinical Trials Group | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Brown University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Johnson and Johnson | For profit | 1 | 0 | 1 | 2013 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2003 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2008 |
| The National Centre in HIV Epidemiology and Clinical Research, Sydney | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Barcelona | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2006 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Boehringer Ingelheim | For profit | NDA2 | Jun 22, 2005 |
| Boehringer Ingelheim | For profit | NDA | Jun 22, 2005 |